nasal device

Presentation of Positive Preclinical Results for CP024 Nasal Growth Hormone

Critical Pharmaceuticals to Present Positive Preclinical Data on Nasal Growth Hormone 01/11/2010 09:00

Critical Pharmaceuticals to Present Positive Preclinical Data on Nasal Growth Hormone

Critical Pharmaceuticals, an emerging biotechnology company, will present positive preclinical results from its CP024 program for growth hormone deficiency at the AAPS Annual Meeting in New Orleans (14-18 November) and Marcus Evans Peptide Formulation and Product Development Forum in Vienna (2-3 December). CP024 is a nasal spray of human growth hormone (hGH) developed using Critical Pharmaceuticals proprietary CriticalSorb™ technology and supported by funding from the Wellcome Trust.

“We are delighted to have achieved exceptional bioavailability and tolerability of human growth hormone delivered nasally using our CriticalSorb™ technology ” said Professor Lisbeth Illum, CEO of Critical Pharmaceuticals. “As we move into Phase 1 clinical studies, we look forward to demonstrating the potential of CP024 to provide patients with an attractive alternative to frequent injection of human growth hormone and other complex biological drugs.”

CriticalSorb™ is an absorption promoter that is widely applicable to the non-invasive delivery of not just human growth hormone, but many other biological drugs. CriticalSorb™ is a ‘GRAS’ (generally regarded as safe) material that is already marketed in various drug products for intravenous and oral administration with an excellent safety and tolerability profile in humans.

As well as presenting the latest results on CP024, Professor Lisbeth Illum and Dr Andy Lewis (Director Operations at Critical Pharmaceuticals) will present the latest developments with Critical Pharmaceuticals CriticalSorb™ and CriticalMix™ drug delivery technologies.

CP024 Nasal hGH

measuring height

CP024 has completed two Phase 1 clinical trials where our intranasal growth hormone has shown comparable activity to injection.

Read more

CriticalSorb Technology

nasal device

CriticalSorb enables the non-invasive nasal delivery delivery of high-value biologic products and challenging small molecule drugs.

Read more

Professor Lisbeth Illum
“We are delighted to have achieved exceptional bioavailability and tolerability of human growth hormone delivered nasally using our CriticalSorb™ technology. As we move into Phase 1 clinical studies, we look forward to demonstrating the potential of CP024 to provide patients with an attractive alternative to frequent injection of human growth hormone and other complex biological drugs.”